Marketdash
Back to News

Novo Nordisk's Alzheimer's Trial Flops, But Analysts Say Don't Panic

MarketDash Editorial Team
12 days ago
Novo Nordisk's semaglutide failed to slow Alzheimer's progression in phase 3 trials, sending shares lower. But Wall Street says the miss was expected and won't derail the company's growth story.

Novo Nordisk A/S (NVO) shares took a hit Monday after the Danish pharmaceutical giant released topline results from its evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer's disease. The verdict? Not great. The two-year studies failed to confirm that semaglutide—the blockbuster ingredient behind Ozempic and Wegovy—was any better than placebo at slowing cognitive decline.

The trials measured progression using the Clinical Dementia Rating – Sum of Boxes (CDR-SB) score, a standard metric for tracking dementia severity. Novo Nordisk had bet that semaglutide's anti-inflammatory and neuroprotective properties might translate from diabetes and obesity into brain health, based on real-world evidence studies, preclinical models, and post-hoc analyses from earlier trials. That bet didn't pay off.

Wall Street Wasn't Holding Its Breath

The good news? Nobody was really expecting a miracle. Goldman Sachs acknowledged the disappointment but emphasized that the miss won't materially alter the company's trajectory. "Our expectations into the trial were low, as we forecast 5% probability of c.$4bn in peak sales for semaglutide in Alzheimer's disease," the bank noted Monday.

Analyst James Quigly pointed out that some investors had been worried about broader risks to Novo Nordisk's medium-term growth, particularly heading into 2026. But he argued that consensus estimates have already been drifting lower after recent announcements highlighted various headwinds. In other words, the market had already started pricing in a tougher road ahead.

Downgrades and Price Target Cuts

Still, the trial failure prompted some Wall Street repositioning. BMO Capital Markets maintained its Market Perform rating but chopped its price forecast from $50 down to $46, reflecting a more conservative outlook now that the Alzheimer's option is off the table. HSBC went further, downgrading Novo Nordisk from Buy to Hold on Monday.

The question now is whether Novo Nordisk's core diabetes and obesity franchises can carry the load, or whether concerns about 2026 growth will keep weighing on sentiment. For now, analysts seem to think the Alzheimer's setback is just that—a setback, not a catastrophe.

Price Action: NVO stock rebounded Tuesday, trading up 4.14% to $46.83 as investors digested the news and decided the damage was already done.

Back to News

Novo Nordisk's Alzheimer's Trial Flops, But Analysts Say Don't Panic

MarketDash Editorial Team
12 days ago
Novo Nordisk's semaglutide failed to slow Alzheimer's progression in phase 3 trials, sending shares lower. But Wall Street says the miss was expected and won't derail the company's growth story.

Novo Nordisk A/S (NVO) shares took a hit Monday after the Danish pharmaceutical giant released topline results from its evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer's disease. The verdict? Not great. The two-year studies failed to confirm that semaglutide—the blockbuster ingredient behind Ozempic and Wegovy—was any better than placebo at slowing cognitive decline.

The trials measured progression using the Clinical Dementia Rating – Sum of Boxes (CDR-SB) score, a standard metric for tracking dementia severity. Novo Nordisk had bet that semaglutide's anti-inflammatory and neuroprotective properties might translate from diabetes and obesity into brain health, based on real-world evidence studies, preclinical models, and post-hoc analyses from earlier trials. That bet didn't pay off.

Wall Street Wasn't Holding Its Breath

The good news? Nobody was really expecting a miracle. Goldman Sachs acknowledged the disappointment but emphasized that the miss won't materially alter the company's trajectory. "Our expectations into the trial were low, as we forecast 5% probability of c.$4bn in peak sales for semaglutide in Alzheimer's disease," the bank noted Monday.

Analyst James Quigly pointed out that some investors had been worried about broader risks to Novo Nordisk's medium-term growth, particularly heading into 2026. But he argued that consensus estimates have already been drifting lower after recent announcements highlighted various headwinds. In other words, the market had already started pricing in a tougher road ahead.

Downgrades and Price Target Cuts

Still, the trial failure prompted some Wall Street repositioning. BMO Capital Markets maintained its Market Perform rating but chopped its price forecast from $50 down to $46, reflecting a more conservative outlook now that the Alzheimer's option is off the table. HSBC went further, downgrading Novo Nordisk from Buy to Hold on Monday.

The question now is whether Novo Nordisk's core diabetes and obesity franchises can carry the load, or whether concerns about 2026 growth will keep weighing on sentiment. For now, analysts seem to think the Alzheimer's setback is just that—a setback, not a catastrophe.

Price Action: NVO stock rebounded Tuesday, trading up 4.14% to $46.83 as investors digested the news and decided the damage was already done.